Enolase 1 (ENO1) compositions and uses thereof
View Patent ↗The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.
1. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of an enolase 1 (Eno1) polypeptide or a fragment thereof; and
(b) a muscle targeting moiety,
wherein the muscle targeting moiety and the Eno1 polypeptide or a fragment thereof are in a complex.
2. The pharmaceutical composition of claim 1 , wherein the Eno1 polypeptide is human Eno1 polypeptide.
3. The pharmaceutical composition of claim 1 , wherein the composition further comprises a microparticle, a nanoparticle, an in situ forming composition, or a liposome.
4. The pharmaceutical composition of claim 1 , wherein the muscle targeting moiety is a skeletal muscle targeting moiety.
5. The pharmaceutical composition of claim 1 , wherein the composition is formulated for parenteral administration.
6. The pharmaceutical composition of claim 1 , wherein the composition is formulated for oral administration.
7. The pharmaceutical composition of claim 1 , wherein the composition is formulated for intramuscular administration, intravenous administration, or subcutaneous administration.
8. A method of decreasing blood glucose in a subject with elevated blood glucose, the method comprising administering to the subject the pharmaceutical composition of claim 1 , thereby decreasing blood glucose in the subject.
9. A method of treating diabetes in a subject, the method comprising administering to the subject the pharmaceutical composition of claim 1 , thereby treating diabetes in the subject.
10. The method of claim 9 , wherein the diabetes is type 2 diabetes or type 1 diabetes.
11. The method of claim 8 , wherein the Eno1 polypeptide is administered parenterally.
12. The method of claim 11 , wherein the Eno1 polypeptide is administered by a route selected from the group consisting of intramuscular, intravenous, and subcutaneous.
13. The method of claim 8 , wherein the subject is human.
14. The method of claim 9 , wherein the Eno1 polypeptide is administered parenterally.
15. The method of claim 14 , wherein the Eno1 polypeptide is administered by a route selected from the group consisting of intramuscular, intravenous, and subcutaneous.
16. The method of claim 9 , wherein the subject is human.